New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
10:04 EDTCNC, HNT, GILD, CI, HS, MOH, UNH, WCG, AGP, AET, HUM, WLPGilead criticized by insurance trade group for 'astronomical' hep C drug price
In a post to its Coverage blog, America's Health Insurance Plans stated that Hepatitis C treatment Sovaldi has shown "tremendous results" and is the "kind of medical innovation we need to sustain," but claims the drug’s maker, Gilead (GILD), is taking "advantage of a lack of competition – has priced it at an astronomical level that is not sustainable for consumers, innovation, or society." America’s Health Insurance Plans, or AHIP, is the national trade association representing the health insurance industry. Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP). Reference Link
News For GILD;HUM;UNH;HNT;AET;MOH;CNC;AGP;HS;WLP;WCG;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 7, 2014
06:15 EDTHUMHumana raises FY14 revenue $48B-$49B from $47B-$49B, consensus $48.64B
Subscribe for More Information
06:11 EDTHUMHumana to inititae $500M accelerated repurchase program after market close
Subscribe for More Information
06:10 EDTHUMHumana reports Q3 EPS $1.85, consensus $2.31
Reports Q3 revenue $12.24B, consensus $12.34B
06:07 EDTHUMHumana expects 2015 individual Medicare Advantage membership to grow to 255K
Subscribe for More Information
06:07 EDTHUMHumana to inititae $500M accelerated repurchase program after market close
Subscribe for More Information
06:07 EDTHUMHumana sees FY15 revenue $53.5B-$54.5B, consensus $53.66B
Subscribe for More Information
06:06 EDTHUMHumana sees meaningful increase in enterprise wide benefit of higher membership
The company said, "We expect the strong value proposition we provide our members, such as high Star quality ratings, relatively flat premiums and benefits and stable provider networks, will position us well for further membership growth and increasing return on capital.”
06:05 EDTHUMHumana sees FY15 EPS $8.50-$9.00, consensus $8.83
Subscribe for More Information
06:05 EDTHUMHumana narrows FY14 adjusted EPS to $7.40-$7.60 from $7.25-$7.75
FY14 EPS consensus of $7.75
06:05 EDTHUMHumana reports Q3 EPS $1.85, consensus $2.31
Subscribe for More Information
November 6, 2014
16:00 EDTGILDOptions Update; November 6, 2014
Subscribe for More Information
15:27 EDTHUMNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Humana (HUM), consensus $2.00; Brookfield Asset Management (BAM), one estimate 33c; Magnum Hunter (MHR), consensus (16c); Cooper Tire & Rubber (CTB), consensus 72c; E. W. Scripps (SSP), consensus 6c; Isis Pharmaceuticals (ISIS), consensus (20c); ViaSat (VSAT), consensus 15c; Dresser-Rand (DRC), consensus 63c; Intercept Pharmaceuticals (ICPT), consensus ($1.10).
15:13 EDTGILDAmerican Association for Study of Liver Diseases to hold a meeting
Subscribe for More Information
13:22 EDTMOHMolina Healthcare price target raised to $58 from $53 at Wedbush
Subscribe for More Information
12:50 EDTCNCCentene management to meet with Oppenheimer
Subscribe for More Information
12:20 EDTGILDStocks with call strike movement; RIG GILD
Transocean (RIG) February 33 call option implied volatility decreased 7% to 42, Gilead (GILD) May 130 call option implied volatility increased 2% to 38 according to IVolatility.
11:01 EDTCICigna, CSMS-IPA launch collaborative care initiative
Cigna and the Connecticut State Medical Society-IPA launched a collaborative care initiative to improve patient access to health care, enhance care coordination. The program became effective October 1.
09:40 EDTGILDActive equity options trading
Subscribe for More Information
09:25 EDTHUMHumana November weekly volatility elevated into Q3 and outlook
Subscribe for More Information
08:39 EDTGILDGilead submits NDA to FDA for elvitegravir, emtricitabine, tenofovir alafenamid
Gilead Sciences announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg for the treatment of HIV-1 infection in adults. The data submitted in the NDA support the use of the regimen among adult and adolescent treatment-naïve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. Gilead plans to submit a regulatory application for E/C/F/TAF in the European Union by the end of 2014.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use